• John F. Ryley
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 96)


The ultimate aim of those involved in the discovery and development of new antifungal drugs is to provide more effective and acceptable treatment for the unfortunate victims of fungal attack (as well as to generate more profit for their sustaining organisations!). The basic purpose of this section is not to teach clinicians how to do their job - though hopefully clinicians reading it will be stimulated to think again about their current attitudes and approaches to fungal diseases. Rather, I have sought for chapters that highlight the limitations of presently available treatments and that indicate directions in which further research is required. Clinical feedback is essential if research management is to be supportive and basic researchers realistic in their endeavours. Marguerite Roberts has written from her very down-to-earth experience of dermatology in a number of our local hospitals in the Manchester area (Chap. 13), and my long-standing friend Jack Sobel has highlighted some of the problems he faces in a hospital situation when confronted with the more refractory forms of fungal vaginitis (Chap. 14).


Fungal Disease Antifungal Drug Acceptable Treatment Clinical Usage Fungal Attack 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • John F. Ryley

There are no affiliations available

Personalised recommendations